Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07513129
- Phase
- PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Lymphoma
- T-cell Acute Lymphoblastic Leukemia
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 30 Years
- Healthy Volunteers
- Not accepted
Interventions
- Venetoclax — DRUGGiven by mouth
- Dexamethasone — DRUGGiven by mouth or IV
- Bortezomib — DRUGGiven subcutaneously or IV
- Daratumumab — DRUGGiven by IV
Study Details
This is an open-label, single institution, Phase 1 study of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult participants with relapsed or refractory T-ALL or T-LBL
Key Dates
- Start date
- Sep 1, 2026
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2031
Study Design
- Enrollment
- 18 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment with Venetoclax, Dexamethasone, Bortezomib, and Daratumumab (VDBD)All participants must complete a screening clinic visit, cycle 1 day 1 (- 28 days), day 1 visits for each new cycle (- 7 days), and an end-of-treatment visit (- 7 days).
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Miriam B Garcia, DO(713) 745-4312
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT MD Anderson | Houston | Texas | 77030 | Miriam B Garcia, DO (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site
Related Studies
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALEPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant SurvivorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 AntigenPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas